Entera Bio Ltd. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ENTX Nasdaq 2836 enterabio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Entera Bio Ltd.

Entera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting - Aug 4th, 2026 6:30 am
Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference - Jul 31st, 2026 2:30 pm
Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement - Jul 27th, 2026 6:30 am
Entera Bio Stock Rallies 35% in a Month: Here's What You Should Know - Jul 21st, 2026 8:39 am
ENTX Stock On Track For Best Day In Over 5 Years — What’s Driving The Rally? - Jun 22nd, 2026 12:29 pm
Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis - Jun 22nd, 2026 6:30 am
Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026 - Jun 16th, 2026 6:33 am
ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis) - Jun 15th, 2026 6:45 am
Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation - May 28th, 2026 6:50 am
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs - May 8th, 2026 2:05 pm
Entera Bio (ENTX) Upgraded to Buy: Here's What You Should Know - Apr 29th, 2026 10:00 am
Entera Bio Touts EB613 Oral Anabolic Tablet as Osteoporosis Care Gap Persists, Phase III Near - Apr 24th, 2026 5:33 pm
BriefCast Publishes Transcript: Entera Bio's Osteoporosis KOL Roundtable on EB613 - Oral Anabolic Tablet Opportunity - Apr 20th, 2026 9:59 am
Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613 - Apr 14th, 2026 6:45 am
Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds - Apr 2nd, 2026 6:45 am
Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates - Mar 27th, 2026 2:05 pm
Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis - Mar 4th, 2026 6:30 am
Matricelf Ltd. (TASE: MTLF) Appoints Ron Mayron as Chairman of the Board - Feb 27th, 2026 5:00 am
Entera Bio to Participate in the Leerink Partners 2026 Global Healthcare Conference - Feb 26th, 2026 6:00 am
Opko Health Inc. (OPK) Builds Value Through Partnerships and Innovation - Feb 17th, 2026 6:42 pm